Related Experiment Video

Updated: Aug 14, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger

Gregory E Kobak1, Todd MacKenzie, Ronald J Sokol

  • 1Pediatric Liver Center and Section of Pediatric Gastroenterology, University of Colorado Health Sciences Center, Denver, CO, USA.

The Journal of Pediatrics
|September 3, 2004
PubMed

Insights

Younger children with chronic hepatitis B (HBV) show a better response to interferon treatment. This study indicates that age is a significant factor in treatment effectiveness for pediatric HBV patients.

Area of Science:

  • Hepatology
  • Pediatric Gastroenterology
  • Virology

Background:

  • Chronic hepatitis B (HBV) infection is a significant global health concern in children.
  • Effective antiviral therapies are crucial for managing pediatric chronic HBV.
  • Interferon therapy has been used, but its efficacy in different pediatric age groups requires further investigation.

Purpose of the Study:

  • To evaluate the effectiveness of interferon-alpha2b in children with chronic hepatitis B.
  • To determine if younger children (< or =5 years) exhibit an improved response to interferon therapy compared to older children.
  • To identify factors influencing treatment response in pediatric HBV patients.

Main Methods:

  • A retrospective chart review was conducted on 22 pediatric patients diagnosed with chronic hepatitis B.
  • Patients were treated with interferon-alpha2b, with ages ranging from 17 months to 17 years.
  • Treatment response was assessed based on serological markers (HBeAg, Anti-HBe, HBsAg, Anti-HBs), HBV DNA levels, and alanine aminotransferase/aspartate aminotransferase (ALT/AST) normalization.

Main Results:

  • Overall, 48% of patients responded to interferon treatment, defined by serological and biochemical normalization at 6 months post-treatment.
  • A significantly higher response rate was observed in children aged 5 years or younger (78%) compared to those older than 5 years (23%).
  • Younger age at the time of treatment initiation was strongly associated with a better treatment response (P =.005).

Conclusions:

  • Interferon therapy demonstrates potentially greater efficacy in younger children with chronic hepatitis B.
  • Age is a critical factor to consider when determining the optimal treatment strategy for pediatric HBV.
  • Further prospective studies are warranted to confirm these findings and optimize interferon treatment protocols for children.
Abstract

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...